Search

Your search keyword '"Tabernero, J"' showing total 1,723 results
Start Over Author "Tabernero, J" Search Limiters Available in Library Collection
1,723 results on '"Tabernero, J"'

4. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

Author

Ducreux, M., Abou-Alfa, G.K., Bekaii-Saab, T., Berlin, J., Cervantes, A., de Baere, T., Eng, C., Galle, P., Gill, S., Gruenberger, T., Haustermans, K., Lamarca, A., Laurent-Puig, P., Llovet, J.M., Lordick, F., Macarulla, T., Mukherji, D., Muro, K., Obermannova, R., O’Connor, J.-M., O’Reilly, E.M., Osterlund, P., Philip, P., Prager, G., Ruiz-Garcia, E., Sangro, B., Seufferlein, T., Tabernero, J., Verslype, C., Wasan, H., and Van Cutsem, E.

Published
2023
Full Text
View/download PDF

5. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer

Author

Martini, G., Belli, V., Napolitano, S., Ciaramella, V., Ciardiello, D., Belli, A., Izzo, F., Avallone, A., Selvaggi, F., Menegon Tasselli, F., Santaniello, W., Franco, R., Puig, I., Ramirez, L., Chicote, I., Mancuso, F., Caratu, G., Serres, X., Fasani, R., Jimenez, J., Ros, J., Baraibar, I., Mulet, N., Della Corte, C.M., Troiani, T., Vivancos, A., Dienstmann, R., Elez, E., Palmer, H.G., Tabernero, J., Martinelli, E., Ciardiello, F., and Argilés, G.

Published
2023
Full Text
View/download PDF

12. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

Author

Borazanci, E., Schram, A.M., Garralda, E., Brana, I., Vieito Villar, M., Spreafico, A., Oliva, M., Lakhani, N.J., Hoffman, K., Hallett, R.M., Maetzel, D., Hua, F., Hilbert, J., Giblin, P., Anido, J., Kelly, A., Vickers, P.J., Wasserman, R., Seoane, J., Siu, L.L., Hyman, D.M., Hoff, D.V., and Tabernero, J.

Published
2022
Full Text
View/download PDF

20. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

Author

Yoshino, T., Argilés, G., Oki, E., Martinelli, E., Taniguchi, H., Arnold, D., Mishima, S., Li, Y., Smruti, B.K., Ahn, J.B., Faud, I., Chee, C.E., Yeh, K.-H., Lin, P.-C., Chua, C., Hasbullah, H.H., Lee, M.A., Sharma, A., Sun, Y., Curigliano, G., Bando, H., Lordick, F., Yamanaka, T., Tabernero, J., Baba, E., Cervantes, A., Ohtsu, A., Peters, S., Ishioka, C., and Pentheroudakis, G.

Published
2021
Full Text
View/download PDF

25. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Author

Gyawali, B., de Vries, E.G.E., Dafni, U., Amaral, T., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez-Roca, C., Kiesewetter, B., Oosting, S., Passaro, A., Pentheroudakis, G., Piccart, M., Roitberg, F., Tabernero, J., Tarazona, N., Trapani, D., Wester, R., Zarkavelis, G., Zielinski, C., Zygoura, P., and Cherny, N.I.

Published
2021
Full Text
View/download PDF

27. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer

Author

Segal, NH, Tie, J, Kopetz, S, Ducreux, M, Chen, E, Dienstmann, R, Hollebecque, A, Reilley, MJ, Elez, E, Cosaert, J, Cain, J, Soo-Hoo, Y, Hewson, N, Cooper, ZA, Kumar, R, Tabernero, J, Segal, NH, Tie, J, Kopetz, S, Ducreux, M, Chen, E, Dienstmann, R, Hollebecque, A, Reilley, MJ, Elez, E, Cosaert, J, Cain, J, Soo-Hoo, Y, Hewson, N, Cooper, ZA, Kumar, R, and Tabernero, J

Abstract

BACKGROUND: To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab (anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti-tumour effect in patients with metastatic colorectal cancer (mCRC). METHODS: COLUMBIA-1 (NCT04068610) was a Phase Ib (feasibility; Part 1)/Phase II (randomised; Part 2) trial in patients with treatment-naïve microsatellite stable mCRC. Patients in Part 2 were randomised to receive standard-of-care (control arm) or standard-of-care plus durvalumab and oleclumab (experimental arm). Primary objectives included safety and efficacy. RESULTS: Seven patients were enrolled in Part 1 and 52 in Part 2 (n = 26 in each arm). Grade ≥3 treatment-emergent adverse events (TEAE) occurred in 80.8% and 65.4% of patients in the control and experimental arms of Part 2, respectively, with 26.9% and 46.3% experiencing serious TEAEs. The confirmed objective response rate (ORR) was numerically higher in the experimental arm compared with the control arm (61.5% [95% confidence interval (CI), 40.6-79.8] vs 46.2% [95% CI, 26.6-66.6]) but did not meet the statistically significant threshold in either arm. CONCLUSION: The safety profile of FOLFOX and bevacizumab in combination with durvalumab and oleclumab was manageable; however, the efficacy results do not warrant further development of this combination in patients with microsatellite stable mCRC. REGISTRATION: NCT04068610.

Published
2024

29. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Author

Addeo, A., Albiges, L., Ascierto, P.A., Banerjee, S., Barlesi, F., Caldas, C., Cardoso, F., Cervantes, A., Chaberny, I.F., Cherny, N.I., Choueiri, T.K., Chua, M.L.K., Criscitiello, C., Curigliano, G., de Azambuja, E., De Ruysscher, D., de Vries, E., Dent, R., Douillard, J.Y., D’Ugo, D., Dziadziuszko, R., Faivre-Finn, C., Felip, E., Garassino, M., Garrido, P., Girard, N., Glynne-Jones, R., Golfinopoulos, V., Haanen, J., Hamilton, E., Jänne, P.A., Jordan, K., Kanesvaran, R., Kim, S.B., Liebert, U.G., Lordick, F., Machiels, J.P., Michielin, O., Mok, T.S.K., Morgan, G., Obermannova, R., Park, K., Passaro, A., Pentheroudakis, G., Peters, S., Reck, M., Salazar Soler, R., Scotté, F., Senan, S., Sessa, C., Smyth, E., Soo, R., Soria, J.C., Spicer, J., Strasser, F., Tabernero, J., Tan, D.S.W., Trapani, D., Van Cutsem, E., van Halteren, H., van Schil, P.E., Veronesi, G., Yang, J., and Garassino, M.C.

Published
2020
Full Text
View/download PDF

32. JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions

Author

Yoshino, T., Pentheroudakis, G., Mishima, S., Overman, M.J., Yeh, K.-H., Baba, E., Naito, Y., Calvo, F., Saxena, A., Chen, L.-T., Takeda, M., Cervantes, A., Taniguchi, H., Yoshida, K., Kodera, Y., Kitagawa, Y., Tabernero, J., Burris, H., and Douillard, J.-Y.

Published
2020
Full Text
View/download PDF

34. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO

Author

Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G.S., Ikeda, M., Lim, H.-Y., Ho, G.F., Choo, S.P., Ren, Z., Malhotra, H., Ueno, M., Ryoo, B.-Y., Kiang, T.C., Tai, D., Vogel, A., Cervantes, A., Lu, S.-N., Yen, C.-J., Huang, Y.-H., Chen, S.-C., Hsu, C., Shen, Y.-C., Tabernero, J., Yen, Y., Hsu, C.-H., Yoshino, T., and Douillard, J.-Y.

Published
2020
Full Text
View/download PDF

36. 93P Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R)

Author

Rossi, A., primary, Braña, I., additional, Villar, M. Vieito, additional, Casal, G. Alonso, additional, Santa Gadea, O. Saavedra, additional, Mirallas, O., additional, Bardaji, M.J. Lostes, additional, Galvao, V., additional, Laimito, K.I. Rojas, additional, Oberoi, A., additional, Pretelli, G., additional, Morillo, B. Ortega, additional, Sanz, M., additional, Izquierdo, S. Aguilar, additional, Raskina, K., additional, Dienstmann, R., additional, Vivancos, A., additional, Tabernero, J., additional, Garralda, E., additional, and Calvo, A. Hernando, additional

Published
2024
Full Text
View/download PDF

37. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

Author

Pant, S, Schuler, M, Iyer, G, Witt, O, Doi, T, Qin, S, Tabernero, J, Reardon, D, Massard, C, Minchom, A, Lugowska, I, Carranza, O, Arnold, D, Gutierrez, M, Winter, H, Stuyckens, K, Crow, L, Najmi, S, Hammond, C, Thomas, S, Santiago-Walker, A, Triantos, S, Sweiti, H, Loriot, Y, Greco, M, Coward, J, Joshua, A, Karapetis, C, Hart, C, Zhang, A, Prenen, H, Goeminne, J, Machiels, J, Rottey, S, Corassa, M, Molin, G, Tiscoski, K, Jardim, D, Mak, M, Fu, W, Yao, H, Huang, J, Jiang, H, Chen, B, Yan, D, Yang, Y, Le Tourneau, C, Penel, N, Salas, S, Blay, J, Brachet, P, Durando, X, Emambux, S, Ravaud, A, Folprecht, G, Ahrens, M, Golf, A, Haag, G, Lordick, F, Desuki, A, Cazzaniga, M, Ciardiello, F, Milella, M, Koyama, T, Hirooka, Y, Okamoto, W, Aogi, K, Kuboki, Y, Lee, J, Kim, S, Ahn, M, Chang, J, Kim, Y, Nam, D, Park, J, Paz-Ares, L, Moreno, V, Cervantes, A, Calvo, M, Falcon, A, Gonzalez, A, Martinez Bueno, A, Garcia-Corbacho, J, Longo, F, Yen, C, Chen, J, Hou, M, Chao, Y, Rau, K, Chiu, T, Feng, Y, Hsu, C, Huang, W, Lai, K, Yeh, S, Palmer, D, Welsh, L, Plummer, R, Bilen, M, Arrowsmith, E, Spigel, D, Zandberg, D, Doroshow, D, Lu-Emerson, C, Moezi, M, Paulson, S, Ward, P, Chaves, J, Grigg, C, Hussein, A, Manda, S, Monticelli, M, Qamar, R, Richey, S, Tamura, D, Wilks, S, Pant S., Schuler M., Iyer G., Witt O., Doi T., Qin S., Tabernero J., Reardon D. A., Massard C., Minchom A., Lugowska I., Carranza O., Arnold D., Gutierrez M., Winter H., Stuyckens K., Crow L., Najmi S., Hammond C., Thomas S., Santiago-Walker A., Triantos S., Sweiti H., Loriot Y., Greco M. A., Coward J., Joshua A., Karapetis C., Hart C., Zhang A., Prenen H., Goeminne J. -C., Machiels J. -P., Rottey S., Corassa M., Molin G. Z. D., Tiscoski K., Jardim D. L. F., Mak M., Fu W., Yao H., Huang J., Jiang H., Chen B., Yan D., Yang Y., Le Tourneau C., Penel N., Salas S., Blay J. -Y., Brachet P. -E., Durando X., Emambux S., Ravaud A., Folprecht G., Ahrens M., Golf A., Haag G. M., Lordick F., Desuki A., Cazzaniga M., Ciardiello F., Milella M., Koyama T., Hirooka Y., Okamoto W., Aogi K., Kuboki Y., Lee J., Kim S. -B., Ahn M. -J., Chang J. H., Kim Y. -M., Nam D. -H., Park J. -S., Paz-Ares L., Moreno V., Cervantes A., Calvo M., Falcon A., Gonzalez A., Martinez Bueno A., Garcia-Corbacho J., Longo F., Yen C. -J., Chen J. -S., Hou M. -F., Chao Y., Rau K. -M., Chiu T. -J., Feng Y. -H., Hsu C. -H., Huang W. -T., Lai K. -M., Yeh S. -P., Palmer D., Welsh L., Plummer R., Bilen M., Arrowsmith E., Spigel D. R., Zandberg D. P., Doroshow D., Lu-Emerson C., Moezi M., Paulson S., Reardon D., Ward P., Chaves J., Grigg C., Hussein A., Manda S., Monticelli M., Qamar R., Richey S. L., Tamura D., Wilks S., Pant, S, Schuler, M, Iyer, G, Witt, O, Doi, T, Qin, S, Tabernero, J, Reardon, D, Massard, C, Minchom, A, Lugowska, I, Carranza, O, Arnold, D, Gutierrez, M, Winter, H, Stuyckens, K, Crow, L, Najmi, S, Hammond, C, Thomas, S, Santiago-Walker, A, Triantos, S, Sweiti, H, Loriot, Y, Greco, M, Coward, J, Joshua, A, Karapetis, C, Hart, C, Zhang, A, Prenen, H, Goeminne, J, Machiels, J, Rottey, S, Corassa, M, Molin, G, Tiscoski, K, Jardim, D, Mak, M, Fu, W, Yao, H, Huang, J, Jiang, H, Chen, B, Yan, D, Yang, Y, Le Tourneau, C, Penel, N, Salas, S, Blay, J, Brachet, P, Durando, X, Emambux, S, Ravaud, A, Folprecht, G, Ahrens, M, Golf, A, Haag, G, Lordick, F, Desuki, A, Cazzaniga, M, Ciardiello, F, Milella, M, Koyama, T, Hirooka, Y, Okamoto, W, Aogi, K, Kuboki, Y, Lee, J, Kim, S, Ahn, M, Chang, J, Kim, Y, Nam, D, Park, J, Paz-Ares, L, Moreno, V, Cervantes, A, Calvo, M, Falcon, A, Gonzalez, A, Martinez Bueno, A, Garcia-Corbacho, J, Longo, F, Yen, C, Chen, J, Hou, M, Chao, Y, Rau, K, Chiu, T, Feng, Y, Hsu, C, Huang, W, Lai, K, Yeh, S, Palmer, D, Welsh, L, Plummer, R, Bilen, M, Arrowsmith, E, Spigel, D, Zandberg, D, Doroshow, D, Lu-Emerson, C, Moezi, M, Paulson, S, Ward, P, Chaves, J, Grigg, C, Hussein, A, Manda, S, Monticelli, M, Qamar, R, Richey, S, Tamura, D, Wilks, S, Pant S., Schuler M., Iyer G., Witt O., Doi T., Qin S., Tabernero J., Reardon D. A., Massard C., Minchom A., Lugowska I., Carranza O., Arnold D., Gutierrez M., Winter H., Stuyckens K., Crow L., Najmi S., Hammond C., Thomas S., Santiago-Walker A., Triantos S., Sweiti H., Loriot Y., Greco M. A., Coward J., Joshua A., Karapetis C., Hart C., Zhang A., Prenen H., Goeminne J. -C., Machiels J. -P., Rottey S., Corassa M., Molin G. Z. D., Tiscoski K., Jardim D. L. F., Mak M., Fu W., Yao H., Huang J., Jiang H., Chen B., Yan D., Yang Y., Le Tourneau C., Penel N., Salas S., Blay J. -Y., Brachet P. -E., Durando X., Emambux S., Ravaud A., Folprecht G., Ahrens M., Golf A., Haag G. M., Lordick F., Desuki A., Cazzaniga M., Ciardiello F., Milella M., Koyama T., Hirooka Y., Okamoto W., Aogi K., Kuboki Y., Lee J., Kim S. -B., Ahn M. -J., Chang J. H., Kim Y. -M., Nam D. -H., Park J. -S., Paz-Ares L., Moreno V., Cervantes A., Calvo M., Falcon A., Gonzalez A., Martinez Bueno A., Garcia-Corbacho J., Longo F., Yen C. -J., Chen J. -S., Hou M. -F., Chao Y., Rau K. -M., Chiu T. -J., Feng Y. -H., Hsu C. -H., Huang W. -T., Lai K. -M., Yeh S. -P., Palmer D., Welsh L., Plummer R., Bilen M., Arrowsmith E., Spigel D. R., Zandberg D. P., Doroshow D., Lu-Emerson C., Moezi M., Paulson S., Reardon D., Ward P., Chaves J., Grigg C., Hussein A., Manda S., Monticelli M., Qamar R., Richey S. L., Tamura D., and Wilks S.

Abstract

Background: FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours. Methods: The single-arm, phase 2 RAGNAR study was conducted at 156 investigative centres (hospitals or oncology practices that are qualified oncology study centres) across 15 countries. The study consisted of four cohorts based on tumour histology and patient age; the results reported in this Article are for the primary cohort of the study, defined as the Broad Panel Cohort, which was histology-agnostic. We recruited patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4 alterations (mutations or fusions according to local or central testing). Eligible patients had disease progression on at least one previous line of systemic therapy and no alternative standard therapy available to them, and an Eastern Cooperative Oncology Group performance status of 0–1 (or equivalent for adolescents aged 12–17 years). Patients received once-daily oral erdafitinib (8 mg/day with provision for pharmacodynamically guided up-titration to 9 mg/day) on a continuous 21-day cycle until disease progression or intolerable toxicity. The primary endpoint was objective response rate by independent review committee according to Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, or Response Assessment In Neuro-Oncology (RANO). The primary analysis was conducted on the treated population of the Broad Panel Cohort. This ongoing study is registered with ClinicalTrials.gov, number NCT04083976. Findings: Patients were recruited between Dec 5, 2019, and Feb 15, 2022. Of 217 patients treated with erdafitinib, 97 (45%) pa

Published
2023

38. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

Author

Vidal, J., Bellosillo, B., Santos Vivas, C., García-Alfonso, P., Carrato, A., Cano, M.T., García-Carbonero, R., Élez, E., Losa, F., Massutí, B., Valladares-Ayerbes, M., Viéitez, J.M., Manzano, J.L., Azuara, D., Gallego, J., Pairet, S., Capellá, G., Salazar, R., Tabernero, J., Aranda, E., and Montagut, C.

Published
2019
Full Text
View/download PDF

39. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Author

Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Kato, K., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Nakajima, T.E., Shitara, K., Kawakami, H., Tsushima, T., Yoshino, T., Lordick, F., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., and Douillard, J -Y

Published
2019
Full Text
View/download PDF

40. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Author

Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Kato, K., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Nakajima, T.E., Shitara, K., Kawakami, H., Narita, Y., Yoshino, T., Van Cutsem, E., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., and Douillard, J -Y

Published
2019
Full Text
View/download PDF

41. Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—a global phase III study

Author

Yoshino, T., Portnoy, D.C., Obermannová, R., Bodoky, G., Prausová, J., Garcia-Carbonero, R., Ciuleanu, T., García-Alfonso, P., Cohn, A.L., Van Cutsem, E., Yamazaki, K., Lonardi, S., Muro, K., Kim, T.W., Yamaguchi, K., Grothey, A., O’Connor, J., Taieb, J., Wijayawardana, S.R., Hozak, R.R., Nasroulah, F., and Tabernero, J.

Published
2019
Full Text
View/download PDF

42. 116TiP Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer

Author

Van Cutsem, E., primary, Fakih, M., additional, Segal, N.H., additional, Johnson, B., additional, Kardosh, A., additional, Philipovskiy, A., additional, Krishnamurthi, S., additional, Gold, P.J., additional, Dekervel, J., additional, Schlechter, B.L., additional, Grossman, J., additional, Fernandez, M.E. Elez, additional, Vardiashvili, N., additional, Azambuja, A.A., additional, Eng, C., additional, Ducreux, M.P., additional, André, T., additional, Tabernero, J., additional, Lenz, H.J., additional, and Hidalgo, M., additional

Published
2023
Full Text
View/download PDF

44. Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)

Author

Marabelle, A., Andtbacka, R., Harrington, K., Melero, I., Leidner, R., de Baere, T., Robert, C., Ascierto, P.A., Baurain, J -F, Imperiale, M., Rahimian, S., Tersago, D., Klumper, E., Hendriks, M., Kumar, R., Stern, M., Öhrling, K., Massacesi, C., Tchakov, I., Tse, A., Douillard, J -Y, Tabernero, J., Haanen, J., and Brody, J.

Published
2018
Full Text
View/download PDF

45. Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies

Author

Atkins, M., Banerji, U., Bates, S., Bogaerts, J., Calvo, E., De Braud, F., Douillard, J.Y., Giaccone, G., Keegan, P., Kumar, R., LoRusso, P., Marabelle, A., Perrone, A., Pignatti, F., Plummer, R., Seymour, L., Schwartz, G., Shalabi, A., Shapiro, G., Siu, L.L., Smoragiewicz, M., Tabernero, J., Therasse, P., and Yang, A.

Published
2018
Full Text
View/download PDF

48. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS

Author

Yoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T.W., Ismail, F., Tan, I.B., Yeh, K.-H., Grothey, A., Zhang, S., Ahn, J.B., Mastura, M.Y., Chong, D., Chen, L.-T., Kopetz, S., Eguchi-Nakajima, T., Ebi, H., Ohtsu, A., Cervantes, A., Muro, K., Tabernero, J., Minami, H., Ciardiello, F., and Douillard, J.-Y.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results